

Non-clinical study on the development of customized targeted anticancer agent for the treatment of advanced Hepatocellular Carcinoma

Etnova Therapeutics Corp. / R&D Center



ONCOLOGY	Non-Clinical
Product Type	Small molecule
Indication	Advanced Hepatocellular Carcinoma (HCC)
Target	FLT3/VEGFR2/KIT/PDGFR β
MoA(Mechanism of Action)	Multiple Tyrosine Kinase Inhibitor
Competitiveness	ETN101(=MBP-11901) showed complete remission at a specific effective concentration or higher as a result of efficacy evaluation using a non-clinical animal model, and showed superior efficacy than existing targeted anticancer drugs even at low concentrations. In particular, it has secured the efficacy of complete remission or close to complete remission for non-responders of existing anticancer drugs, thereby securing the basis for its use in clinical patients. In addition, it can lead the development of innovative liver cancer-targeting anticancer drugs that have secured safety and effectiveness as they have a sufficient margin of safety compared to efficacy.
Development Stage	Non-Clinical
Route of Administration	Oral administration